BIOA News
Archived Headlines
- US IPO Week Ahead: Natural gas producer leads week with three sizable IPOs 09/20/24
- Obesity biotech BioAge Labs sets terms for $135 million IPO 09/18/24
- US IPO Week Ahead: Quiet week expected after flurry of biotech IPOs 09/13/24
- Metabolic disease biotech BioAge Labs files for a $100 million IPO 09/03/24
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
US IPO Weekly Recap: Three sizable deals trade up
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Natural gas producer BKV (BKV) priced its IPO below the range to raise $270 million at a $1.5 billion market capitalization. Operating primarily in the Barnett Shale, the...read more
BioAge Labs prices IPO at $18 midpoint after upsizing again
BioAge Labs, a Phase 2 biotech developing obesity therapies by targeting metabolic aging, raised $198 million by offering 11.0 million shares at $18, within the range of $17 to $19. The company had originally planned to sell 7.5 million shares before raising...read more
Obesity biotech BioAge Labs increases shares by 40% ahead of $189 million IPO
BioAge Labs, a Phase 2 biotech developing obesity therapies by targeting metabolic aging, raised the proposed deal size for its upcoming IPO on Wednesday. The Richmond, CA-based company now plans to raise $189 million by offering 10.5 million shares at a price...read more